Contact the Editorial Desk
Correspondence on citations, corrections, and research updates — the kind of message this file is built to receive.
Editorial correspondence
Peptide Scienes welcomes mail that makes the investigation more accurate or more current: a citation quoted imprecisely, a newly published trial on CJC-1295, GHK-Cu, semaglutide, or tesamorelin, or a regulatory update that shifts an approval status noted on the references page. This is exactly the message a reporting project most needs, and each one is read with care.
The most useful notes name the exact page, the exact passage in question, and a supporting source — a DOI or PubMed identifier where possible — so a proposed correction can be checked against its source before anything changes.
Editorial mailbox: editors@peptidescienes.com
What the investigation can't do
So no message goes unanswered for the wrong reason: because this is a reporting project rather than a clinical service, it cannot advise on or endorse human use of any peptide covered here, name a dose or schedule for any person, judge whether a cited trial's findings fit someone's specific situation, or help source, sell, or locate any compound from any supplier. It also can't counsel athletes on anti-doping questions, though it's worth stating plainly that CJC-1295 and tesamorelin both sit on the World Anti-Doping Agency's prohibited list.
Semaglutide and tesamorelin are prescription medicines, reachable only through licensed providers. Anyone seeking medical guidance should consult a licensed clinician in their own jurisdiction. Replies aren't guaranteed and can take time; the mailbox is checked periodically rather than continuously.